Future of Cancer Immunotherapy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium History and Evolution of Immunotherapy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Modern era of cancer immunotherapy began in 1994-1996, CTLA-4 controls function and anti-tumor immunity

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium CTLA-4 blockade in metastatic -

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium The Checkpoint Inhibitor, PD-1, amplifies and transforms the field

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Combining PD-1 and CTLA-4 blockade in metastatic melanoma

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium A second key discovery, cell therapy - a complementary effort to target tumors with limited immunogenicity

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 8

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Chimeric Antigen Receptor: CD19CAR T-cell that changed to field

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Major CAR-T Milestones: First Approvals in 2017

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Immunotherapy delivers - 10 FDA immunotherapy approval milestones in 6 years

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium We have made enormous progress with approved drugs, first-in-class treatments and novel treatments.

But none of them are fully curative and many tumors can’t be treated.

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen
immunotherapy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 14

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium And…that’s actually what’s happening in the clinic

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 16

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Better Biomarkers will be able to predict efficacy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Planned Studies: Biomarker Driven
Fix the agents and change biomarkers

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium IO Master Platform Protocol: PD1
Resistance

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen
immunotherapy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 21

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 22

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Response rate not fully correlated with mutational load

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 24

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 25

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen
immunotherapy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium PICI Pancreatic Cancer Clinical Trial

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 28

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Differences in gut microbiome:
anti-PD-1 responders v. non-responders

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium PICI0014: Evaluate safety, tolerability and efficacy of microbiome therapy in metastatic melanoma

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Key questions for next-gen immunotherapy

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium PICI T Cell Engineering Initiative

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium New possibilities for cell engineering

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium NY-ESO-1 engineered TCR & PD-1 knockout

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium New approaches in CAR-T

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Slide 36

Presented By Jeffrey Bluestone at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium